Fagg S L, Dawson-Edwards P, Hughes M A, Latief T N, Rolfe E B, Fielding J W
Br J Urol. 1984 Jun;56(3):296-300. doi: 10.1111/j.1464-410x.1984.tb05390.x.
Cis-diamminedichloroplatinum (DDP) was used as the initial treatment in a pilot study of 17 patients with biopsy-proven transitional cell carcinoma of the bladder. No patient had received any previous radiotherapy or chemotherapy. The clinical stages of the tumours were T2 (2 patients), T3 (13) and T4 (2). Before treatment the tumours were assessed by cystoscopy, biopsy, examination under anaesthesia (EUA), computed axial tomography (CT scan) and ultrasound. DDP was given at a dose of 100 mg/m2 intravenously with hydration using mannitol and saline. Each patient received three treatments at 3-weekly intervals. Twelve days after the third treatment, response was assessed by cystoscopy, biopsy, EUA, CT scan and ultrasound. Eleven of the 17 patients had a partial response. Survival was significantly increased in responders compared with non-responders. Seven patients had a low creatine clearance following treatment, 5 had audiograms showing evidence of ototoxicity and 2 developed leucopenia during treatment. This study confirmed the activity of DDP in bladder cancer and showed that it was active in producing a response in the primary tumour in 11 of 17 patients.
顺二氯二氨铂（DDP）被用作一项针对17例经活检证实为膀胱移行细胞癌患者的初步治疗研究。此前没有患者接受过任何放疗或化疗。肿瘤的临床分期为T2期（2例患者）、T3期（13例）和T4期（2例）。治疗前通过膀胱镜检查、活检、麻醉下检查（EUA）、计算机断层扫描（CT扫描）和超声对肿瘤进行评估。DDP以100 mg/m²的剂量静脉注射，并使用甘露醇和生理盐水进行水化。每位患者每3周接受3次治疗。第三次治疗后12天，通过膀胱镜检查、活检、EUA、CT扫描和超声评估疗效。17例患者中有11例出现部分缓解。与无反应者相比，有反应者的生存期显著延长。7例患者治疗后肌酐清除率较低，5例听力图显示有耳毒性证据，2例在治疗期间出现白细胞减少。这项研究证实了DDP在膀胱癌中的活性，并表明它在17例患者中的11例原发性肿瘤中产生反应方面具有活性。
